当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第3期, 第166-171页
标题:
口服抗凝药的临床治疗研究进展
DOI:
10.5428/pcar20190303
作者:
1. 孟璐1(1.河北医科大学研究生学院 石家庄 050017 2311136730@qq.com)
2. 丁琮洋1(1.河北医科大学研究生学院 石家庄 050017 )
3. 安静1(1.河北医科大学研究生学院 石家庄 050017 )
4. 2(2.河北省人民医院药学部 石家庄 050051 )
5. 李亚静1(1.河北医科大学研究生学院 石家庄 050017 )
6. 李颖2(2.河北省人民医院药学部 石家庄 050051 )
7. 董占军1(1.河北医科大学研究生学院 石家庄 050017 13313213656@126.com)
8. 2(2.河北省人民医院药学部 石家庄 050051 13313213656@126.com)
摘要:
摘要  近年来,随着血栓栓塞性疾病的发病率及死亡率的上升,抗凝药物对于预防和治疗血栓栓塞性疾病具有重要的临床意义和应用价值。临床上口服抗凝药主要分为传统口服抗凝药和新型口服抗凝药。华法林作为临床常用的传统口服抗凝药,存在治疗窗窄、剂量需不断调整、易与药物和食物发生相互作用等不足,造成在临床使用过程中有诸多不便。而新型口服抗凝药,如利伐沙班、阿哌沙班、依度沙班、贝曲沙班、达比加群酯等,在治疗血栓栓塞性疾病过程中具有无需频繁调整剂量、无需常规监测凝血功能、出血率低等优点,较华法林优势明显,其安全性和有效性均不劣于华法林。本文对近年来国内外发表的药物治疗血栓栓塞性疾病研究进展的相关文献进行综述,为临床规范化使用口服抗凝药提供参考。
欢迎阅读《药学服务与研究》!您是该文第 36 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 孟璐1,丁琮洋1,安静1,2,李亚静1,李颖2,董占军1,2. 口服抗凝药的临床治疗研究进展[J]. 药学服务与研究. 2019; 19(3): 166-171.
英文著录格式 MENG Lu1,DING Congyang1,AN Jing1,2,LI Yajing1,LI Ying2,DONG Zhanjun1,2. Research progress in clinical treatment of oral anticoagulants[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(3): 166-171.
参考文献:
1. 李海刚,范蓉,马宁,等.华法林药代动力学过程影响因素研究进展[J].中国临床药理学与治疗学,2017,22(11):1292-1298.
2. 束长城,侯振世.新型口服抗凝药在房颤患者治疗中的研究进展[J].中国当代医药,2019,26(4):26-28.
3. Verhoef T I,Redekop W K,Daly A K,et al.Pharmacogenetic-guided dosing of coumarin anticoagulants:algorithms for warfarin,acenocoumarol and phenprocoumon[J].Br J Clin Pharmacol,2014,77(4):626-641.
4. 项海燕,唐燕华.华法林抗凝治疗的临床应用概述[J].重庆医学,2012,41(16):1652-1654.
5. 中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82.
6. 康俊萍.华法林临床应用要点[J].中国医刊,2014,49(1):11-14.
7. Flora D R,Rettie A E,Brundage R C,et al.CYP2C9 genotype-dependent warfarin pharmacokinetics:impact of CYP2C9 genotype on R- and S-warfarin and their oxidative metabolites[J].J Clin Pharmacol,2017,57(3):382-393.
8. Kaye J B,Schultz L E,Steiner H E,et al.Warfarin pharmacogenomics in diverse populations[J].Pharmacotherapy,2017,37(9):1150-1163.
9. Gemmati D,Burini F,Talarico A,et al.The active metabolite of warfarin (3′-hydroxywarfarin) and correlation with INR,warfarin and drug weekly dosage in patients under oral anticoagulant therapy:a pharmacogenetics study[J].PLoS One,2016,11(9):e0162084.
10. Ray W A,Chung C P,Murray K T,et al.Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding[J].Gastroenterology,2016,151(6):1105-1112.
11. Johnson J A,Caudle K E,GONG Li,et al.Clinical pharmacogenetics implementation consortium(CPIC) guidelines for pharmacogenetics-guided warfarin dosing:2017 update[J].Clin Pharmacol Ther,2017,102(3):397-404.
12. Shaw K,Amstutz U,Kim R B,et al.Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy[J].Ther Drug Monit,2015,37(4):428-436.
13. Shaw K,Amstutz U,Hildebrand C,et al.VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children[J].Pediatr Blood Cancer,2014,61(6):1055-1062.
14. WEI Meng,YE Fei,XIE Dujiang,et al.A new algorithm to predict warfarin dose from polymorphisms of CYP4F2,CYP2C9 and VKORC1 and clinical variables:derivation in Han Chinese patients with non valvular atrial fibrillation[J].Thromb Haemost,2012,107(6):1083-1091.
15. Fenger-Eriksen C,Münster A M,Grove E L.New oral anticoagulants:clinical indications,monitoring and treatment of acute bleeding complications[J].Acta Anaesthesiol Scand,2014,58(6):651-659.
16. 窦丽稳,高伟波,朱继红.新型口服抗凝药物急诊应用指导[J].中国全科医学,2017,20(23):2900-2905.
17. 周建光,周颖奇.新型口服抗凝药的特点和临床研究[J].临床药物治疗杂志,2013,11(5):8-14.
18. 王兵,刘颖,刘登科,等.直接Ⅹa因子抑制剂贝曲沙班[J].现代药物与临床,2015,30(2):217-221.
19. Huisman M V,Klok F A.Pharmacological properties of betrixaban[J].Eur Heart J Suppl,2018,20(Suppl E):E12-E15.
20. Stangier J.Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate[J].Clin Pharmacokinet,2008,47(5):285-295.
21. Hankey G J,Eikelboom J W.Dabigatran etexilate:a new oral thrombin inhibitor[J].Circulation,2011,123(13):1436-1450.
22. Deftereos S,Anatoliotakis N,Giannopoulos G,et al.Novel direct factor Ⅱa and Ⅹa inhibitors:mechanisms of action and preclinical studies[J].Curr Clin Pharmacol,2012,7(3):149-165.
23. Patel M R,Mahaffey K W,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.
24. Sherwood M W,Nessel C C,Hellkamp A S,et al.Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin:ROCKET AF trial[J].J Am Coll Cardiol,2015,66(21):2271-2281.
25. The EINSTEIN-PE investigators,Buller H R,Prins M H,et al.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J].N Engl J Med,2012,366(14):1287-1297.
26. Granger C B,Alexander J H,McMurray J J V,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365(11):981-992.
27. Schafer J H,Casey A L,Dupre K A,et al.Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease[J].Ann Pharmacother,2018,52(11):1078-1084.
28. The Hokusai-VTE investigators,Buller H R,Décousus H,et al.Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J].N Engl J Med,2013,369(15):1406-1415.
29. Giugliano R P,Ruff C T,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
30. Beyer-Westendorf J,Verhamme P,Bauersachs R.Betrixaban for prevention of venous thromboembolism in acute medically ill patients[J].Eur Heart J Suppl,2018,20(Suppl E):E16-E22.
31. Gibson C M,Korjian S,Chi G,et al.Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients:an APEX trial substudy[J].J Am Heart Assoc,2017,6(7):e006015.
32. Cohen A T,Harrington R A,Goldhaber S Z,et al.Extended thromboprophylaxis with betrixaban in acutely ill medical patients[J].N Engl J Med,2016,375(6):534-544.
33. Yee M K,Nafee T,Daaboul Y,et al.Increased benefit of betrixaban among patients with a history of venous thromboembolism:a post-hoc analysis of the APEX trial[J].J Thromb Thrombolysis,2017,45(1):1-8.
34. Connolly S J,Ezekowitz M D,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
35. Schulman S,Kearon C,Kakkar A K,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J].N Engl J Med,2009,361(24):2342-2352.
36. 汤洁,彭佳惠,张梦媛,等.新型口服抗凝药物拮抗剂的研究进展[J].中国临床保健杂志,2019,22(1):130-134.
37. 刘萧,洪葵.新型口服抗凝药相关出血的治疗策略及其特异性拮抗剂[J].中华心血管病杂志,2016,44(11):921-924.